Sparks commentary - Immix Biopharma

Healthcare

Sparks - Immix Biopharma

More on this equity
Immix (NASDAQ: IMMX) presents positive data in ALA
Published by Arron Aatkar

Immix Biopharma has announced that it will be presenting a clinical update from the NEXICART-1 trial, conducted in Israel, at the 66th American Society of Hematology Annual Meeting on 9 December 2024. The trial is assessing lead CAR-T candidate, NXC-201, as a potential treatment for amyloid light chain amyloidosis (ALA). The presentation will correspond to 16 patients (prior update was 13 patients) with median four prior lines of therapy. Encouragingly, for the 16 patients, a complete response rate of 75% (12/16 patients) has been reported. We understand that more detailed data will be reported at the conference in December.

Immix is also evaluating NXC-201 as a potential treatment for ALA in the US-based NEXICART-2 trial, which commenced in July 2024. An update for this trial is also anticipated within Q424.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free